CNP and DPYSL2 mRNA expression and promoter methylation levels in brain of Alzheimer's disease patients

Journal of Alzheimer's Disease

Volumn 33, Issue 2, 2013, Pages 349-355

  Natalia Silva, Patrícia ^a   Furuya, Tatiane Katsue ^a   Sampaio Braga, Ianna ^a   Rasmussen, Lucas Trevizani ^b   De Labio, Roger Willian ^b   Bertolucci, Paulo Henrique ^a   Chen, Elizabeth Suchi ^a   Turecki, Gustavo ^c   Mechawar, Naguib ^c   Payão, Spencer Luiz ^a,b   Mill, Jonathan ^d   Cardoso Smith, Marília ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b FACULDADE DE MEDICINA DE MARÍLIA   (Brazil)

^c MCGILL UNIVERSITY   (Canada)

^d KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

CNP; DPYSL2; epigenetics; gene expression; mRNA

Indexed keywords

2',3' CYCLIC NUCLEOTIDE 3' PHOSPHODIESTERASE; APOLIPOPROTEIN E; COLLAPSIN RESPONSE MEDIATOR PROTEIN 2; MESSENGER RNA; MYELIN;

ALZHEIMER DISEASE; ARTICLE; AUDITORY CORTEX; AUTOPSY; BRAIN REGION; BRAIN TISSUE; COGNITION; CONTROLLED STUDY; DISEASE ASSOCIATION; DOWN REGULATION; ENTORHINAL CORTEX; EPIGENETICS; GENE FREQUENCY; GENETIC REGULATION; HIPPOCAMPUS; HUMAN; HUMAN TISSUE; MASS SPECTROMETRY; MYELINATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN METHYLATION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STRUCTURE ACTIVITY RELATION;

EID: 84872452263     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2012-121192     Document Type: Article

References (21)

1. Nussbaum RL, Ellis CE (2003) Alzheimer's disease and Parkinson's disease. N Engl J Med 348, 1356-1364. (Pubitemid 36384104)
2. Reinikainen KJ, Pitkanen A, Riekkinen PJ (1989) 2,3-cyclic nucleotide-3-phosphodiesterase activity as an index of myelin in the post-mortem brains of patients with Alzheimer's disease. Neurosci Lett 106, 229-232. (Pubitemid 19285991)
3. Iraola-Guzman S, Estivill X, Rabionet R (2011) DNA methylation in neurodegenerative disorders:Amissing link between genome and environment? Clin Genet 80, 1-14.
4. Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML, Pahwa JS, Moskvina V, Dowzell K,Williams A, Jones N, Thomas C, Stretton A, Morgan AR, Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, Rubinsztein DC, Gill M, Lawlor B, Lynch A, Morgan K, Brown KS, Passmore PA, Craig D, McGuinness B, Todd S, Holmes C, Mann D, Smith AD, Love S, Kehoe PG, Hardy J, Mead S, Fox N, Rossor M, Collinge J, Maier W, Jessen F, Schurmann B, van den Bussche H, Heuser I, Kornhuber J,Wiltfang J, Dichgans M, Frolich L, Hampel H, Hull M, Rujescu D, Goate AM, Kauwe JS, Cruchaga C, Nowotny P, Morris JC, Mayo K, Sleegers K, Bettens K, Engelborghs S, De Deyn PP, Van BroeckhovenC,Livingston G, Bass NJ, Gurling H, McQuillin A, Gwilliam R, Deloukas P, Al-Chalabi A, Shaw CE, Tsolaki M, Singleton AB, Guerreiro R, Muhleisen TW, Nothen MM, Moebus S, Jockel KH, Klopp N,Wichmann HE, Carrasquillo MM, Pankratz VS, Younkin SG, Holmans PA, O'Donovan M, Owen MJ, Williams J (2009) Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet 41, 1088-1093.
5. Lambert JC, Heath S, Even G, Campion D, Sleegers K, Hiltunen M, Combarros O, Zelenika D, Bullido MJ, Tavernier B, Letenneur L, Bettens K, Berr C, Pasquier F, Fievet N, Barberger-Gateau P, Engelborghs S, De Deyn P, Mateo I, Franck A, Helisalmi S, Porcellini E, Hanon O, de Pancorbo MM, Lendon C, Dufouil C, Jaillard C, Leveillard T, Alvarez V, Bosco P, Mancuso M, Panza F, Nacmias B, Bossu P, Piccardi P, Annoni G, Seripa D, Galimberti D, Hannequin D, Licastro F, Soininen H, Ritchie K, Blanche H, Dartigues JF, Tzourio C, Gut I,Van BroeckhovenC, Alperovitch A, Lathrop M, Amouyel P (2009) Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet 41, 1094-1099.
6. Mastroeni D, Grover A, Delvaux E, Whiteside C, Coleman PD, Rogers J (2011) Epigenetic changes in Alzheimer's disease: Decrements in DNA methylation. Neurobiol Aging 31, 2025-2037.
7. Roher AE, Weiss N, Kokjohn TA, Kuo YM, Kalback W, Anthony J,Watson D, Luehrs DC, Sue L,Walker D, Emmerling M, Goux W, Beach T (2002) Increased A beta peptides and reduced cholesterol and myelin proteins characterize white matter degeneration in Alzheimer's disease. Biochemistry 41, 11080-11090. (Pubitemid 35034009)
8. Vlkolinsky R, Cairns N, Fountoulakis M, Lubec G (2001) Decreased brain levels of 2,3-cyclic nucleotide-3-phosphodiesterase in Down syndrome and Alzheimer's disease. Neurobiol Aging 22, 547-553. (Pubitemid 32607738)
9. de la Monte SM, Wells SE, Hedley-Whyte T, Growdon JH (1989) Neuropathological distinction between Parkinson's dementia and Parkinson's plus Alzheimer's disease. Ann Neurol 26, 309-320. (Pubitemid 19230298)
10. Hensley K, Venkova K, Christov A, Gunning W, Park J (2011) Collapsin response mediator protein-2: An emerging pathologic feature and therapeutic target for neurodisease indications. Mol Neurobiol 43, 180-191.
11. Soutar MP, Thornhill P, Cole AR, Sutherland C (2009) Increased CRMP2 phosphorylation is observed in Alzheimer's disease; does this tell us anything about disease development? Curr Alzheimer Res 6, 269-278.
12. LiT,Hawkes C, QureshiHY, Kar S, PaudelHK(2006) Cyclindependent protein kinase 5 primes microtubule-associated protein tau site-specifically for glycogen synthase kinase 3beta. Biochemistry 45, 3134-3145. (Pubitemid 43376332)
13. Lubec G, Nonaka M, Krapfenbauer K, Gratzer M, Cairns N, Fountoulakis M (1999) Expression of the dihydropyrimidinase related protein 2 (DRP-2) in Down syndrome and Alzheimer's disease brain is downregulated at the mRNA and dysregulated at the protein level. J Neural Transm Suppl 57, 161-177.
14. Johnston-Wilson NL, Sims CD, Hofmann JP, Anderson L, Shore AD, Torrey EF, Yolken RH (2000) Disease-specific alterations in frontal cortex brain proteins in schizophrenia, bipolar disorder, and major depressive disorder. The Stanley Neuropathology Consortium. Mol Psychiatry 5, 142-149. (Pubitemid 30229428)
15. Edgar PF, Douglas JE, Cooper GJ, Dean B, Kydd R, Faull RL (2000) Comparative proteome analysis of the hippocampus implicates chromosome 6q in schizophrenia. Mol Psychiatry 5, 85-90. (Pubitemid 30088457)
16. McKhann G, Drachman D, Folstein M, Katzman R, Price D, StadlanEM(1984) Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA work group under the auspices of department of health and human services task force on Alzheimer's disease. Neurology 34, 939-944. (Pubitemid 14076461)
17. Ehrich M, Nelson MR, Stanssens P, Zabeau M, Liloglou T, Xinarianos G, Cantor CR, Field JK, van den Boom D (2005) Quantitative high-throughput analysis of DNA methylation patterns by base-specific cleavage and mass spectrometry. Proc Natl Acad Sci U S A 102, 15785-15790. (Pubitemid 41552820)
18. Hixson JE, Vernier DT (1990) Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 31, 545-548. (Pubitemid 20107994)
19. Hinman JD, Chen CD, Oh SY, Hollander W, Abraham CR (2007) Age-dependent accumulation of ubiquitinated 2,3-cyclic nucleotide 3-phosphodiesterase in myelin lipid rafts. Glia 56, 118-133. (Pubitemid 350172737)
20. Lappe-Siefke C, Goebbels S, Gravel M, Nicksch E, Lee J, Braun PE, Griffiths IR, Nave KA (2003) Disruption of Cnp1 uncouples oligodendroglial functions in axonal support and myelination. Nat Genet 33, 366-374. (Pubitemid 36278853)
21. Sultana R, Perluigi M, Butterfield DA (2006) Redox proteomics identification of oxidatively modified proteins in Alzheimer's disease brain and in vivo and in vitro models of AD centered around Abeta(1-42). J Chromatogr B Analyt Technol Biomed Life Sci 833, 3-11.